亿帆医药(002019.SZ)子公司亿帆制药签署关于一项创新药独家协议

Group 1 - The company Yifan Pharmaceutical (002019.SZ) has signed exclusive agreements with Shangde Yaoyuan and Tianjin Shangde, granting Yifan the exclusive rights to develop, produce, and commercialize the drug ACT001 in specified regions and fields [1] - Yifan Pharmaceutical will pay a total of 1 billion yuan as an upfront payment, with options for additional payments based on milestones or net sales revenue sharing [1] - The drug ACT001, developed by Shangde Yaoyuan, is a novel class 1 innovative drug that has undergone multiple clinical trials in China, the US, and Australia, targeting small cell lung cancer brain metastases and gliomas [2] Group 2 - ACT001 has received "breakthrough therapy" designation from the National Medical Products Administration for its indication in small cell lung cancer brain metastases and is currently in phase III clinical trials [2] - The drug works by inhibiting NF-κB and STAT3 signaling pathways in the tumor microenvironment, reducing DNA repair capabilities of tumor cells, and enhancing the effects of chemotherapy and immunotherapy [2] - The introduction of this innovative anti-tumor drug will effectively supplement the company's oncology pipeline while avoiding the high costs and time associated with developing new drugs from scratch [2]